Fig. 4From: Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United StatesNumber of irAEs grouped by 18 tissue or organ disorders for FDA-approved ICIs. Nivolumab, pembrolizumab and atezolizumab had the highest case numbers of serious irAEs. “Respiratory, thoracic and mediastinal disorders” was consistently among the top 3 for each ICIBack to article page